Search - tctmd.com

Displaying 41 - 60 of 68

Sort: Relevancy | Date

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Conference News EAS 2018

Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention

Yael L. Maxwell

May 07, 2018

News Daily News

LPA Variants Linked With CHD Events in Statin-Treated Patients

Michael O'Riordan

May 03, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for January 2018

Shelley Wood

January 31, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Conference News SCCT 2017

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

Yael L. Maxwell

July 10, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Herbals and the Heart: New Review Seeks to Sum Up Dearth of Data on Effects and Hazards

Shelley Wood

February 28, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Features

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

Shelley Wood

December 30, 2016

News Daily News

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Michael O'Riordan

September 16, 2016

News Daily News

Demasiados Elementos en Juego: La Existencia de Diferentes y Discordantes Directrices Hace que la Valoración del Riesgo de ECV sea Confusa

Michael O'Riordan

September 16, 2016

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

News Daily News

Sin Dinero Ni Medicamentos: Barreras Globales a la Prevención Secundaria de la Enfermedad Cardiovascular

Caitlin E. Cox

October 27, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

Yael L. Maxwell

August 12, 2015

News Industry News

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

June 19, 2015

Advertisement

Top News in Prevention: 2018

Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention

LPA Variants Linked With CHD Events in Statin-Treated Patients

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

TCTMD’s Top 10 Most Popular Stories for January 2018

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Herbals and the Heart: New Review Seeks to Sum Up Dearth of Data on Effects and Hazards

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Demasiados Elementos en Juego: La Existencia de Diferentes y Discordantes Directrices Hace que la Valoración del Riesgo de ECV sea Confusa

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Sin Dinero Ni Medicamentos: Barreras Globales a la Prevención Secundaria de la Enfermedad Cardiovascular

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content